At the Cutting Edge of Cancer Research: How AcceGen Power the Next Wave of Cancer Breakthroughs

From the pioneering HeLa cells—the world’s first immortalized human cells—to today’s sophisticated patient-derived xenograft (PDX) models, cancer research has progressed at a remarkable pace. Concurrently, therapeutic strategies have evolved from conventional chemotherapy and radiotherapy to precision approaches such as targeted therapies, immune checkpoint inhibitors, CAR-T cell therapy, and mRNA-based cancer vaccines.

As oncology enters a transformative era, researchers require more than fundamental cellular models. What they demand now are accurate, reliable, and biologically relevant in vitro systems that can reflect the intricate complexity of human tumors. While classic tumor cell lines remain essential for drug screening and mechanistic investigations, the demand for next-generation models—those that capable of capturing tumor heterogeneity, microenvironmental dynamics, and genetic variability-is growing rapidly.

AcceGen: Fueling Innovation in Cancer Research

At AcceGen, we are proud to support cancer researchers with a comprehensive portfolio of well-characterized, clinically annotated tumor cell models. Our collection encompasses a broad range of cancer types-from prevalent types like breast, lung, and colorectal to rare and treatment-resistant malignancies such as melanoma, glioblastoma, and pancreatic cancer.

To meet the demands of today's frontline oncology research, we offer:

✅ Stably transfected tumor cell lines expressing high-priority CAR-T targets including CD19, BCMA, HER2, and EGFR – perfect for evaluating CAR-T cell cytotoxicity.
✅ Isogenic CRISPR knockout models for functional genomics, drug resistance mechanism studies, and gene function exploration.
✅ In vivo imaging-grade reporter cell lines featuring Luciferase and GFP, enabling real-time tumor tracking, longitudinal studies, and high-throughput drug screening.

These advanced experimental systems empower researchers to dissect tumor biology, validate novel drug candidates, uncover resistance mechanisms, and optimize immunotherapies—all with greater precision and translational relevance.

Advancing Toward a Cancer-Free Future

Cancer remains one of the most formidable challenges in modern medicine-but with better tools and more advanced models, transformative progress is within reach. Whether developing next-generation immunotherapies or exploring novel gene-editing strategies, AcceGen is here to accelerate your journey with the thoroughly characterized cellular tools to accelerate cancer research.

Explore our full catalog of tumor cell lines here and power your next breakthrough.